US stock · Healthcare sector · Diagnostics & Research
Company Logo

CareDx, Inc

CDNANASDAQ

16.56

USD
+0.30
(+1.85%)
Market Closed
-11.68P/E
-97Forward P/E
-0.53P/E to S&P500
886.578MMarket CAP
- -Div Yield
Upcoming Earnings
22 Feb-27 Feb
Shares Short
1/13/23
4.95M
Short % of Float
9.42%
Short % of Shares Outs.
9.25%
% Held by Insiders
3.27%
% Held by Institutions
103.03%
Beta
0.99
PEG Ratio
-1.98
52w. high/low
46.88/10.50
Avg. Daily Volume
1.05M
Return %
Stock
S&P 500
1 year
(61.06)
(8.58)
3 years
(34.28)
23.39
5 years
- -
- -
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
30.80
5.07
41.27
18.75
79.92
13.04
99.83
39.16
47.82
10.68
18.04
10.50
Currency: USD
- -
- -
- -
- -
- -
- -
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
2.77
3.00
4.70
2.37
2.46
2.07
2.15
3.01
4.13
5.63
5.99
Earnings per share
- -
- -
- -
- -
- -
- -
(0.69)
(0.48)
0.13
(1.16)
(2.39)
(2.38)
(1.31)
(0.52)
(0.40)
(0.58)
(1.41)
FCF per share
- -
- -
- -
- -
- -
- -
(0.26)
(0.09)
(0.70)
(0.92)
(1.03)
(0.62)
(0.32)
(0.15)
0.50
(0.75)
(1.04)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
0.02
0.01
0.13
0.10
0.03
0.01
0.20
0.08
0.22
0.38
0.51
Book Value per sh.
- -
- -
- -
- -
- -
- -
(19.97)
(20.44)
7.10
2.49
1.18
(0.26)
2.69
2.35
5.97
8.84
8.48
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
7
7
6
12
16
23
36
42
46
53
53
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(12.5)
(54.5)
(87.1)
(122.0)
(11.7)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(0.5)
(2.2)
(2.3)
(4.1)
(0.5)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
20
22
27
28
41
48
77
127
192
296
319
Operating margin
- -
- -
- -
- -
- -
- -
(11.5)%
(3.9)%
4.6%
(42.4)%
(91.9)%
(42.0)%
(20.3)%
(19.3)%
(11.7)%
(10.0)%
(23.1)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
1
1
1
1
3
4
4
6
10
12
15
Net profit (m)
- -
- -
- -
- -
- -
- -
(5)
(4)
1
(14)
(39)
(55)
(47)
(22)
(19)
(31)
(74)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
208.6%
- -
3.9%
3.0%
3.0%
8.3%
5.2%
4.4%
1.0%
Net profit margin
- -
- -
- -
- -
- -
- -
(24.7)%
(16.0)%
2.9%
(48.7)%
(97.1)%
(114.8)%
(61.1)%
(17.3)%
(9.7)%
(10.3)%
(23.3)%
Working capital (m)
- -
- -
- -
- -
- -
- -
1
1
29
24
(14)
(16)
62
37
204
356
318
Long-term debt (m)
- -
- -
- -
- -
- -
- -
13
11
5
13
1
18
- -
- -
16
17
35
Equity (m)
- -
- -
- -
- -
- -
- -
(147)
(151)
41
29
19
(6)
96
99
278
466
437
ROIC
- -
- -
- -
- -
- -
- -
(68.5)%
(61.1)%
(3.0)%
(26.6)%
(105.8)%
(123.0)%
(38.8)%
(18.8)%
(6.3)%
(6.3)%
(15.3)%
Return on capital
- -
- -
- -
- -
- -
- -
(23.9)%
(14.1)%
2.3%
(21.8)%
(51.3)%
(61.5)%
(34.0)%
(15.8)%
(5.4)%
(5.7)%
(13.5)%
Return on equity
- -
- -
- -
- -
- -
- -
3.4%
2.4%
1.9%
(46.5)%
(202.6)%
904.3%
(48.7)%
(22.2)%
(6.7)%
(6.6)%
(17.0)%
Plowback ratio
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
961.2%
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
3 Nov · 2022 | Q3
All numbers in millions
Total liabilities
$ 108
Total assets
$ 545
Long-term debt
$ 35
Cash and equiv.
$ 83
Goodwill
$ 38
Retained earnings
$ (441)
Common stock
53
Enterprise Value
$ 838
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
38
225
348
Receivables
24
35
60
Inventory
6
10
17
Other
4
100
318
Current assets
72
273
433
Acc. Payable
6
10
13
Debt due
3
2
4
Other
26
58
60
Current liabilities
35
69
77
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
54.22%
57.47%
36.43%
Cash flow
(271.44)%
(204.14)%
(15.55)%
Earnings
63.85%
(4.92)%
(199.81)%
Dividends
- -
- -
- -
Book value
67.78%
(353.10)%
(192.39)%
Insider Trading
Type
Shares
Date
Johnson Alexander L
InKind
417
02/03/23
Johnson Alexander L
InKind
417
02/03/23
Seeto Reginald
InKind
1,228
02/03/23
Seeto Reginald
InKind
1,228
02/03/23
Ronai Abraham
InKind
2,029
02/02/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
38
42
53
59
192
2021
67
74
76
79
296
2022
79
81
79
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.13)
(0.14)
(0.06)
(0.08)
(0.40)
2021
(0.01)
(0.04)
(0.23)
(0.31)
(0.58)
2022
(0.37)
(0.41)
(0.32)
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Diagnostics & Research
CEO:
Dr. Peter Maag
Full-time employees:
633
City:
South San Francisco
Address:
1 Tower Place, 9Th Floor
IPO:
Jul 17, 2014
Website:
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.